A published case series study indicates that TSE can be performed without general anaesthesia
The Scandinavian ChemoTech Medical Affairs team is happy to announce that a landmark study, conducted at the Department of Anaesthesia and Critical Care, All India Institute of Medical Sciences (AIIMS) in India, has shown, in a published case series study, that TSE is safe to be used under conscious sedation without general anaesthesia (GA) with good systemic pain control and sedation.
The case series was published on the 14th of September 2022, in the Saudi Journal of Anaesthesia / Volume 16 / Issue 4 / October-December by the Anaesthesiology team at AIIMS Jodhpur.
The authors of the publication are: Priyanka Sethi, Raksha Vyas, Manbir Kaur, Pradeep Bhatia from the Department of Anaesthesia and Critical Care, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
The study included a cohort of twenty-one patients who received TSE therapy under sedation and pain relief. Out of the 21 patients, four patients were at very high risk for GA and included one case of locally advanced breast cancer, two cases of head & neck (H&N) carcinoma, and one case of chest wall recurrence of oesophageal carcinoma. The high risk was due to medical reasons. All the patients recovered well and no adverse effect was observed.
“We found it safe to perform the TSE therapy without GA. Instead, we used conscious sedation using trans‑nasal humidified rapid‑insufflation ventilatory exchange (THRIVE) and dexmedetomidine infusion. This result shows that treating advanced H&N cancer patients doesn’t necessarily need to be under GA..” - says Dr Manbir Kaur, Department of Anaesthesia and Critical Care, All India Institute of Medical Sciences (AIIMS)
“The finding in this publication is of great importance for us going forward in India as well as the rest of the world. Avoiding GA not only makes the therapy safer and easier to perform but it also makes the therapy, even more cost efficient for both the healthcare system and for the privately paying patients.” - says Dr Suhail Mufti the Medical Adviser for ChemoTech
The publication will be found on ChemoTech’s website www.chemotech.se/chemotech-publications/ or can be downloaded from: www.saudija.org
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
